Jeffrey Cohen
Stock Analyst at Ladenburg Thalmann
(0.94)
# 4,466
Out of 5,182 analysts
18
Total ratings
23.08%
Success rate
-4.91%
Average return
Main Sectors:
Stocks Rated by Jeffrey Cohen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $64 → $66 | $41.50 | +59.04% | 2 | Nov 12, 2025 | |
| CELH Celsius Holdings | Maintains: Neutral | $62 → $58 | $35.25 | +64.54% | 3 | Mar 27, 2025 | |
| ECOR electroCore | Maintains: Buy | $28 → $26 | $6.50 | +300.00% | 2 | Mar 13, 2025 | |
| NUWE Nuwellis | Downgrades: Neutral | n/a | $1.18 | - | 1 | Nov 8, 2023 | |
| SABS SAB Biotherapeutics | Downgrades: Neutral | n/a | $3.85 | - | 1 | Oct 5, 2023 | |
| FBIO Fortress Biotech | Initiates: Buy | $90 | $2.36 | +3,713.56% | 1 | Aug 4, 2022 | |
| OPK OPKO Health | Initiates: Buy | $7 | $1.24 | +464.52% | 1 | Jun 21, 2021 | |
| NNOX Nano-X Imaging | Initiates: Buy | $52 | $2.85 | +1,724.56% | 1 | Apr 19, 2021 | |
| TENX Tenax Therapeutics | Upgrades: Buy | n/a | $14.45 | - | 1 | May 18, 2017 | |
| CNMD CONMED | Downgrades: Neutral | n/a | $39.08 | - | 5 | Apr 27, 2017 |
Harrow
Nov 12, 2025
Maintains: Buy
Price Target: $64 → $66
Current: $41.50
Upside: +59.04%
Celsius Holdings
Mar 27, 2025
Maintains: Neutral
Price Target: $62 → $58
Current: $35.25
Upside: +64.54%
electroCore
Mar 13, 2025
Maintains: Buy
Price Target: $28 → $26
Current: $6.50
Upside: +300.00%
Nuwellis
Nov 8, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
SAB Biotherapeutics
Oct 5, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.85
Upside: -
Fortress Biotech
Aug 4, 2022
Initiates: Buy
Price Target: $90
Current: $2.36
Upside: +3,713.56%
OPKO Health
Jun 21, 2021
Initiates: Buy
Price Target: $7
Current: $1.24
Upside: +464.52%
Nano-X Imaging
Apr 19, 2021
Initiates: Buy
Price Target: $52
Current: $2.85
Upside: +1,724.56%
Tenax Therapeutics
May 18, 2017
Upgrades: Buy
Price Target: n/a
Current: $14.45
Upside: -
CONMED
Apr 27, 2017
Downgrades: Neutral
Price Target: n/a
Current: $39.08
Upside: -